Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195939 | 0.84 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL16190580 | 0.84 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1532632 | 0.84 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL15286426 | 0.82 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL17275158 | 0.82 | ALDH1A1 (0.45) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL19466094 | 0.82 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18120819 | 0.82 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL899233 | 0.79 | GAA (0.40) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL18854349 | 0.78 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2458470 | 0.76 | CYP2C19 (0.48) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562834-B2 | Process for preparing substituted crotonic acids | INTERVET INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562834-B2 | Process for preparing substituted crotonic acids | INTERVET INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2831042-B1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INT BV (NL) | 2019-07-31 | — | — | EP | disclosed |
| US-20190135725-A1 | PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135725-A1 | PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170121265-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121265-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | INTERVET INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| US-6806288-B1 | CYCLOOXYGENASE-2 MEDIATED DISORDERS; REDUCES INFLAMMATION; FEWER SIDE EFFECTS | G.D. SEARLE & CO. | 2004-10-19 | — | — | US | disclosed |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. | 2004-02-26 | — | — | US | disclosed |
| EP-0977748-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6492390-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS. | G.D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1123285-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6271253-B1 | CYCLOOXYGENASE INHIBITORS | G.D. SEARLE & CO. | 2001-08-07 | — | — | US | disclosed |
| US-6077850-A | USEFUL FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 2000-06-20 | — | — | US | disclosed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135725-A1 | PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | CROCC, CMA1, HSD11B1 | GAA 1573/4885MGAM 1515/4885SI 194/4885 |
| US-10562834-B2 | Process for preparing substituted crotonic acids | CROCC, CMA1, HSD11B1 | GAA 1573/4885MGAM 1515/4885SI 194/4885 |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | PTGS1, IL1R1, PTGES2 | GAA 2689/4885MGAM 3917/4885SI 2660/4885 |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | PTGS1, PTGES2, IL1R1 | GAA 1698/4885MGAM 2870/4885SI 2349/4885 |
| US-20170121265-A1 | IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS | CROCC, CMA1, HSD11B1 | GAA 1399/4885MGAM 1626/4885SI 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.